AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
AMCP joined with other national pharmacy stakeholders to urge HHS to authorize pharmacists to order and administer COVID-19 vaccines when they become available.
AMCP joined with other health care stakeholders to urge Congressional leadership to bolster Medicaid funding due to the COVID-19 public health emergency.
July 2020 News & Views includes: Doug Long to Discuss Health Care Trends and Impact of COVID-19 at AMCP Webinar, July 9 at 2pm ET; AMCP Foundation Unveils New Mission Statement, Marks 30 Year Anniversary; David Calabrese, 2020 Avey Award Recipient, Shares Insights on Career and Profession; AMCP Corporate Member Spotlight: Scipher Medicine
CMS outlining proposed changes to the calculation of best price under the Medicaid Drug Rebate Program (MDRP), particularly how manufacturers should account for value-based purchasing programs.
Read this week’s blog to learn how AMCP is taking a stand against racial injustice and starting work to translate broad goals into specific, long-term actions that improve patient outcomes and health equity among all Americans, including Black Americans, indigenous people, and people of color.
